انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
Episode 18. Management of Smoldering Multiple Myeloma
Manage episode 358797279 series 3369804
1. How I Approach Smoldering Myeloma (Vaxman and Gertz):
https://ashpublications.org/blood/article/140/8/828/485274
2. Risk-Stratification Models in SMM:
Mayo 2018 model: https://pubmed.ncbi.nlm.nih.gov/29895887/
PETHEMA (Spanish) model: https://pubmed.ncbi.nlm.nih.gov/17576818/
PANGEA model: https://pubmed.ncbi.nlm.nih.gov/36858677/
IMWG SMM model: https://pubmed.ncbi.nlm.nih.gov/33067414/
3. QuiRedex RCT (Lenalidomide-Dexamethasone vs Observation in High-Risk SMM):
https://pubmed.ncbi.nlm.nih.gov/36067617/
4. ECOG E3A06 RCT (Lenalidomide vs Observation in SMM):
https://pubmed.ncbi.nlm.nih.gov/31652094/
5. Intensive Treatment in High-Risk Smoldering Multiple Myeloma:
GEM-CESAR: https://ashpublications.org/blood/article/140/Supplement%201/292/490268
ASCENT: https://ashpublications.org/blood/article/140/Supplement%201/1830/492739
6. Current Clinical Trial Landscape in Smoldering Myeloma:
https://pubmed.ncbi.nlm.nih.gov/34114943/
7. How Light Chain Proteinuria Modulates Risk of Progression in Patients with sFLC ratio>100 as the only Myeloma-Defining Event?
52 حلقات
Manage episode 358797279 series 3369804
1. How I Approach Smoldering Myeloma (Vaxman and Gertz):
https://ashpublications.org/blood/article/140/8/828/485274
2. Risk-Stratification Models in SMM:
Mayo 2018 model: https://pubmed.ncbi.nlm.nih.gov/29895887/
PETHEMA (Spanish) model: https://pubmed.ncbi.nlm.nih.gov/17576818/
PANGEA model: https://pubmed.ncbi.nlm.nih.gov/36858677/
IMWG SMM model: https://pubmed.ncbi.nlm.nih.gov/33067414/
3. QuiRedex RCT (Lenalidomide-Dexamethasone vs Observation in High-Risk SMM):
https://pubmed.ncbi.nlm.nih.gov/36067617/
4. ECOG E3A06 RCT (Lenalidomide vs Observation in SMM):
https://pubmed.ncbi.nlm.nih.gov/31652094/
5. Intensive Treatment in High-Risk Smoldering Multiple Myeloma:
GEM-CESAR: https://ashpublications.org/blood/article/140/Supplement%201/292/490268
ASCENT: https://ashpublications.org/blood/article/140/Supplement%201/1830/492739
6. Current Clinical Trial Landscape in Smoldering Myeloma:
https://pubmed.ncbi.nlm.nih.gov/34114943/
7. How Light Chain Proteinuria Modulates Risk of Progression in Patients with sFLC ratio>100 as the only Myeloma-Defining Event?
52 حلقات
सभी एपिसोड
×مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.